BioSpace News Archive

Bionano Genomics, Inc. announced that its Chinese OEM partner, Ecobono, a distribution company focused on reproductive health products, has obtained reagent Class I registration from China’s NMPA for Bionano’s DNA isolation products.

Accent Therapeutics today announced the appointments of Jason Sager, M.D. as Chief Medical Officer, Steven Mennen, Ph.D., as Vice President of Pre-Clinical Development and Stuart Ince, Ph.D. as Vice President of Program Leadership.

Meitheal Pharmaceuticals, Inc. announced an exclusive licensing agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. (THDB) to commercialize three insulin biosimilars — insulin aspart, insulin lispro, and insulin glargine — in the U.S.

Collaboration leverages JURA Bio’s T cell receptor (TCR) discovery platform to discover and develop innovative therapies by applying AI and machine learning.

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO).

ProSomnus, Inc. announced the completion of a $10 million convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital, LLC.

Dizal announced that the China National Medical Products Administration has granted priority review status to golidocitinib, Dizal’s investigational JAK1-only inhibitor, for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Coalition to Cure Calpain 3 in partnership with the National Organization for Rare Disorders launched a study with global reach to research Calpainopathy, a rare form of muscular dystrophy that causes progressive muscle weakness and wasting.

Simulations Plus, Inc. today announced it has been awarded a new funded grant from the U.S. Food and Drug Administration.

Nexcella, Inc. a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) designation for NXC-201 for the treatment of a life-threatening blood disorder, Amyloid Light Chain (AL) Amyloidosis.